MPS IIIA Disease Monitoring Program

October 1, 2026 updated by: Ultragenyx Pharmaceutical Inc

Mucopolysaccharidosis Type IIIA (MPS IIIA) Disease Monitoring Program

The main objective of this observational study is to evaluate the long-term safety and effectiveness of rebisufligene etisparvovec for 10 years after rebisufligene etisparvovec administration.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

The UX111-CL401 MPS IIIA Disease Monitoring Program is a prospective, multicenter, long term outcomes study to obtain safety and clinical outcomes data for 10 years after the administration of rebisufligene etisparvovec in either a clinical trial or post-marketing setting.

Study Type

Observational

Enrollment (Estimated)

55

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The DMP population comprises patients with MPS IIIA who received rebisufligene etisparvovec in a clinical trial or have been prescribed (or plan to receive) rebisufligene etisparvovec in a post marketing setting.

Description

Inclusion Criteria:

  • Confirmed diagnosis of MPS IIIA

  • Patient who:

    1. Group 1: Received rebisufligene etisparvovec in a prior interventional clinical trial.

      May be enrolled upon completion of Study ABT-001 (Cohort 4) or end of study (EOS) or early termination (ET) visit from the prior clinical trial (Study ABT-003 or Study LTFU-ABO-102). OR

    2. Group 2: Received (or plans to receive) rebisufligene etisparvovec in a postmarketing setting.

  • Provide informed consent after the nature of the study has been explained, and prior to any research-related procedures. If a minor or an adult with cognitive limitations, willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related procedures.

Exclusion Criteria:

  • Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1: Rebisufligene Etisparvovec in Prior Clinical Study

Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in prior clinical study involving rebisufligene etisparvovec

No investigational/study product will be administered in this DMP.

Group 2: Rebisufligene Etisparvovec in Post-Marketing Setting

Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in a post-marketing setting

No investigational/study product will be administered in this DMP.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Serious Adverse Events (SAEs) Assessed as Related to Rebisufligene Etisparvovec by the Investigator and Targeted Adverse Events (Targeted AEs) Associated with Identified and Potential Risks of UX111 or AAV8 Gene Therapy
Time Frame: 10 Years
10 Years
Bayley Scales of Infant and Toddler Development Cognitive Raw Score Over Time
Time Frame: 10 Years
10 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Medical Director, Ultragenyx Pharmaceuticals Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

October 1, 2038

Study Completion (Estimated)

October 1, 2038

Study Registration Dates

First Submitted

September 25, 2026

First Submitted That Met QC Criteria

October 1, 2026

First Posted (Actual)

October 2, 2026

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

October 1, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe